Skip To Main Content
Şuheda Ataş İpek on Muck Rack

Şuheda Ataş İpek

Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Şuheda Ataş

Contact Şuheda Ataş, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

The Impact of PIK3CA Mutations and Inflammation–Nutritional Biomarkers on Pathological Complete Response in HER2-Positive Early Breast Cancer: A Real-World Cohort Study

|
By Ibrahim Kaplan, Şuheda Ataş İpek, Şendağ Yaslıkaya
| Preprints.org
You are already at the latest version Background/Objectives: Although dual HER2-targeted neoadjuvant therapy improves pathological complete response (pCR) rates in HER2-positive early breast cancer (EBC), a substantial proportion of patients have residual disease. We evaluated the association between PIK3CA mutations, inflammation–nutritional biomarkers, and pCR.
Open in Who Shared Issue with article?

Precision Oncology in Cholangiocarcinoma: Two Fusion-Positive Case Reports and a Literature Review

|
By Şuheda Ataş İpek, Ertugrul Bayram, Şendağ Yaslikaya
| Preprints.org
4. Discussion The management of advanced cholangiocarcinoma has changed considerably over the past decade following the introduction of molecularly targeted therapies. Comprehensive genomic profiling has identified several actionable alterations, allowing treatment to be tailored according to tumor biology rather than anatomical classification alone.
Open in Who Shared Issue with article?
See all 2 articles